Scholarlink

Background <p>Acid peptic disease (APD) is often associated with comorbidities. Choosing a proton pump inhibitor (PPI) is critical in such patients, given the frequent use of multiple concomitant medications in routine clinical practice. This real-world study was planned in India to understand drug utilization and prescription patterns of PPIs in APD patients with comorbidities.</p> Objective <p>The aim was to evaluate the real-world drug utilization patterns of PPIs and to explore the adherence, effectiveness, and tolerability of pantoprazole in APD patients with comorbidities in India.</p> Methods <p>This multicenter, retrospective, electronic medical record–based study analyzed data of adult APD patients with comorbidities treated with PPIs at four Indian outpatient clinics (January 2017–December 2020). Patients aged ≥18 years with at least two follow-up visits were included, and outcomes assessed included utilization patterns, adherence, effectiveness, and tolerability.</p> Results <p>The study included data from 687 patients with APD, who had a mean age of 47.8 years, and 56.6% of them were male. Patients had various comorbidities, and PPIs were co-prescribed with antidiabetics, antiplatelets, antihypertensives, antibiotics, and antithyroid drugs. Pantoprazole was the most commonly prescribed PPI (51.7%), followed by esomeprazole (20.2%), rabeprazole (13.0%), lansoprazole (9.2%), and omeprazole (6.0%). A greater proportion of patients treated with pantoprazole adhered to treatment when compared to other PPIs at follow-up visits. All APD symptoms significantly reduced at follow-up visit 2 compared to baseline across all PPIs (<i>p</i> &lt; 0.05). All PPIs were well-tolerated, with adverse events consistent with their known profiles.</p> Conclusion <p>This real-world study highlighted utilization patterns of PPIs and demonstrated that all PPIs are effective and well-tolerated in managing APD symptoms in patients with comorbidities. Pantoprazole was the most co-prescribed and preferred PPI amongst the prescribed PPIs. These findings provide real-world insights into how PPIs are utilized in Indian patients with APD and comorbidities and may help clinicians make informed decisions when selecting an appropriate PPI in routine practice.</p> Trial Registration <p>The study was registered in the Clinical Trial Registry of India (CTRI number: CTRI/2021/06/034237).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Yogesh Garje,
  • Tanish Modi,
  • Mudit Sabharwal,
  • Sunil Gupta,
  • Rajiv Saikia,
  • Ashwini Satpathy,
  • Shruti Dharmadhikari,
  • Neeraj Markandeywar,
  • Chintan Khandhedia,
  • Amey Mane,
  • Suyog Mehta,
  • Sadhna Joglekar

摘要

Background

Acid peptic disease (APD) is often associated with comorbidities. Choosing a proton pump inhibitor (PPI) is critical in such patients, given the frequent use of multiple concomitant medications in routine clinical practice. This real-world study was planned in India to understand drug utilization and prescription patterns of PPIs in APD patients with comorbidities.

Objective

The aim was to evaluate the real-world drug utilization patterns of PPIs and to explore the adherence, effectiveness, and tolerability of pantoprazole in APD patients with comorbidities in India.

Methods

This multicenter, retrospective, electronic medical record–based study analyzed data of adult APD patients with comorbidities treated with PPIs at four Indian outpatient clinics (January 2017–December 2020). Patients aged ≥18 years with at least two follow-up visits were included, and outcomes assessed included utilization patterns, adherence, effectiveness, and tolerability.

Results

The study included data from 687 patients with APD, who had a mean age of 47.8 years, and 56.6% of them were male. Patients had various comorbidities, and PPIs were co-prescribed with antidiabetics, antiplatelets, antihypertensives, antibiotics, and antithyroid drugs. Pantoprazole was the most commonly prescribed PPI (51.7%), followed by esomeprazole (20.2%), rabeprazole (13.0%), lansoprazole (9.2%), and omeprazole (6.0%). A greater proportion of patients treated with pantoprazole adhered to treatment when compared to other PPIs at follow-up visits. All APD symptoms significantly reduced at follow-up visit 2 compared to baseline across all PPIs (p < 0.05). All PPIs were well-tolerated, with adverse events consistent with their known profiles.

Conclusion

This real-world study highlighted utilization patterns of PPIs and demonstrated that all PPIs are effective and well-tolerated in managing APD symptoms in patients with comorbidities. Pantoprazole was the most co-prescribed and preferred PPI amongst the prescribed PPIs. These findings provide real-world insights into how PPIs are utilized in Indian patients with APD and comorbidities and may help clinicians make informed decisions when selecting an appropriate PPI in routine practice.

Trial Registration

The study was registered in the Clinical Trial Registry of India (CTRI number: CTRI/2021/06/034237).